Fundraising Fox

Exin Therapeutics

YC W25 ↗

San Francisco, US · Founded 2024 · Delaware corporation · 9 employees · 2 known investors

exintherapeutics.com ↗

Exin Therapeutics develops an AI-guided drug discovery platform that uses experimental mouse studies to identify neurological therapies, starting with epilepsies linked to autism and Parkinson's disease. The company trains machine learning models on proprietary multimodal neuroscience data to guide its therapeutic screening process.

BiotechHealthtechNeurotechnologyTherapeuticsin /exin-therapeutics@ExinTxycombinator.com ↗

Founders & leadership· Y Combinator alumni (W25)

GOGabriel Ocana Santero
Gabriel Ocana Santeroin𝕏Founder
MTMarko Tvrdic
Marko Tvrdicin𝕏Founder
IA
Ivan Alex Priela LazarteExecutive Officer, Director

Investors · 2

Y CombinatorSan Francisco · $500K
468 CapitalreportedBerlin

Reported raises · per SEC filings

Form D private placements
▶$2.2MraisedFeb 2026 · 28 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Gabriel Ocana SanteroExecutive Officer, Director
  • Ivan Alex Priela LazarteExecutive Officer, Director
  • Marko TvrdicExecutive Officer, Director
Offering amount
$2.2M
Amount sold
$2.2M
First sale
Nov 2024
Incorporated
Corporation, Delaware, 2024
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news